NasdaqGS:HOOD
NasdaqGS:HOODCapital Markets

Is It Too Late to Consider Robinhood After Its Stunning 205% Rally in 2025?

If you are wondering whether Robinhood Markets has already had its big run or if there is still value on the table, you are not alone. That is exactly what we are going to unpack here. With the stock up 3.8% over the last week, 4.6% over the past month, and an eye catching 204.9% year to date, the market is clearly rethinking what Robinhood is worth. Part of that momentum has been fueled by steady product expansion, as Robinhood has pushed further into retirement accounts, credit products,...
NYSE:PLD
NYSE:PLDIndustrial REITs

The Bull Case For Prologis (PLD) Could Change Following Q4 Earnings And Occupancy Focus - Learn Why

In recent days, investors have been looking ahead to Prologis’ now-past Q4 2025 earnings release as a key checkpoint following recently reported strong Q3 operational results and high portfolio occupancy. This renewed focus on near-term performance underscores how closely the market is watching whether Prologis can sustain leasing momentum and operational strength in its logistics portfolio. We’ll now examine how anticipation around Prologis’ Q4 earnings and its high occupancy levels feeds...
NYSE:ELAN
NYSE:ELANPharmaceuticals

Elanco (ELAN): Valuation Check After Credelio Quattro-CA1 Approval and Growing Wall Street Optimism

Elanco Animal Health (ELAN) just checked two important boxes for investors, pairing a conditional FDA green light for its Credelio Quattro-CA1 parasite treatment with a wave of upbeat Wall Street commentary. See our latest analysis for Elanco Animal Health. The conditional approval lands after a powerful run, with an 84 percent year to date share price return and an 87 percent one year total shareholder return. This signals momentum that still looks more like a turnaround than a trade. If...
NYSE:MDT
NYSE:MDTMedical Equipment

Medtronic (MDT): Revisiting Valuation After a Quietly Strong Share Price Performance This Year

Medtronic (MDT) has quietly outperformed the broader healthcare space this year, and its latest move in refining its device portfolio is giving investors a fresh reason to revisit the stock’s long term trajectory. See our latest analysis for Medtronic. That steady portfolio work is backing up what the market has already started to price in, with a 21.5% year to date share price return and a 23.5% one year total shareholder return suggesting momentum is still quietly building rather than...
NYSE:DIS
NYSE:DISEntertainment

Disney (DIS): Revisiting Valuation After a 9% One-Month Share Price Rebound

Walt Disney (DIS) has been grinding higher lately, and with the stock up about 9% over the past month, investors are starting to revisit whether this long standing media name still offers upside. See our latest analysis for Walt Disney. That 1 month share price return of 8.57% at around $113 suggests momentum is starting to rebuild, even though the year to date share price gain and 1 year total shareholder return remain modest as investors weigh streaming profits against park strength. If...
NasdaqCM:WULF
NasdaqCM:WULFSoftware

TeraWulf (WULF): Assessing Valuation After a Volatile Run and Strong Multi‑Year Shareholder Returns

TeraWulf (WULF) has quietly become one of the more volatile Bitcoin mining plays, with the stock swinging from deep losses to a roughly 127% gain this year as crypto markets recovered. See our latest analysis for TeraWulf. That surge has come with plenty of whiplash, but the 13.22% 90 day share price return and nearly 2,000% three year total shareholder return suggest speculative momentum is still very much alive around TeraWulf’s growth story and risk profile. If TeraWulf’s run has you...
NYSE:ACN
NYSE:ACNIT

Is Accenture Now an Opportunity After a 22% Slide and DCF Upside in 2025?

Wondering if Accenture’s recent slump has finally turned it into a value opportunity, or if the market is telling you to stay cautious? After falling roughly 22.4% year to date and 23.6% over the last year, the stock has started to stabilize, with a 7.5% gain over the past month despite a small dip of 0.5% in the last week. Investors have been reacting to ongoing headlines around tech spending, digital transformation budgets, and consulting demand, all of which feed directly into Accenture’s...
NYSE:BNED
NYSE:BNEDSpecialty Retail

Barnes & Noble Education (BNED) Q4 Loss Narrows, Testing Bearish Profitability Narratives

Barnes & Noble Education (BNED) has just wrapped up FY 2025 with fourth quarter revenue of $278.3 million and a basic EPS of about -$0.67, alongside trailing 12 month revenue of roughly $1.6 billion and EPS of about -$2.50. These figures underscore an earnings profile still under pressure. The company has seen quarterly revenue move from $235.9 million in Q4 FY 2024 through $602.1 million in Q2 FY 2025 before landing at $278.3 million in Q4 FY 2025. EPS has swung from about -$14.95 to as high...